Innokas Medical participated in the project where the regulatory framework for NTNU’s new set of reagents were created.

‍

Tonje S. Steigedal (PhD), working as Business Developer at NTNU Technology Transfer sees Innokas as an excellent partner especially because of its very strong expertise and high-quality output in delivery. She tells that NTNU’s team has been very satisfied with the cooperation with Innokas team, and that the co-operation may continue also in the future. “We needed specific guidance on the regulatory framework for a product, and often regulatory consultants seem to give a lot more information than you need and in very unstructured way. We really appreciated that Innokas were able to provide us clear and concrete advices to enable us to establish an efficient regulatory roadmap. This really added value for us”, Steigedal tells.

‍

NTNU Technology Transfer AS is a Norwegian-based company established in 2003, owned by the Norwegian University of Science and Technology (NTNU) and the Central Norway Regional Health Authority (Helse-Midt Norge). The deepest aim of the company is to lead the way from new ideas and innovations to reality by reducing risks and increasing the commercial value of research results.